Earnings Call Intelligence Subscribe
Home › Call Sheets › REGN › Q2'26
Call sheet · Q2'26

Regeneron Pharmaceuticals (REGN)

Q2'26 earnings call · held 2026-07-30 · compared with the Q1'26 call · management-credibility review
5/12
Disclosure score
3 medium, 3 low flags
Financial quality
Bottom line
The sleeper story is the Sanofi development balance payoff unlocking $500M+ in annual cash flow starting Q3, which explains the aggressive buybacks and will fund the bloated pipeline. The Street sees EYLEA HD's overtaking of EYLEA as validation, but biosimilar entry will crater the franchise faster than modeled, with management already guiding to 'low to mid-teens' sequential declines. The binding constraint isn't competition or innovation, it's FDA manufacturing approvals: EYLEA HD PFS is stuck after multiple PDUFA misses, Limerick disrupted production, and they can't seem to get basic fill-finish right. Most revealing quote: Len admitting they're in 'productive early discussions' with Sanofi on next-gen assets after insisting in Q1 'we can do these things ourselves.' My view changes if they announce a concrete Sanofi deal with economics in Q3, proving they can still execute partnerships.

The 30-second version

  • The Sanofi cash machine turns on: $930M balance repaid, Q3 collaboration revenue to jump by ~$500M+
  • EYLEA HD overtakes EYLEA for first time ($596M vs $412M), but biosimilar storm hits in H2
  • Next-gen Dupixent assets suddenly a collaboration priority after years of going solo

What changed this quarter

MetricQ1'26Q2'26Change
Total Revenue$3.6B (YoY +19%)$4.3B (YoY +17%)Deceleration despite Sanofi tailwind
Non-GAAP EPS$9.47 (YoY +15%)$14.29 (YoY +11%)Growth rate compression
Dupixent Global Sales$4.9B (YoY +31% CC)$6.0B (YoY +38% CC)+700bps YoY acceleration
EYLEA HD US Sales$468M (YoY +52%)$596M (YoY +52%)Maintained 52% growth rate
EYLEA US Sales$473M (YoY -36%)$412M (YoY -45%)Decline accelerating
Libtayo Global Sales$438M (YoY +54%)$489M (YoY +29%)Growth rate halved
Sanofi Collaboration Revenue$1.6B$2.2BAll-time high reached
Free Cash Flow$848M (Q1 only)$1.4B (H1 total)Strong generation continues
R&D Expense$1.4B$1.5B7% sequential increase
GAAP Gross Margin76%78%Still impaired by Limerick

Accountability tracked

7 new promises made5 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full REGN Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.